Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
WNK463 is an inhibitor of WNK lysine-deficient protein kinase 1 (WNK1), WNK2, WNK3, and WNK4 (IC50s = 5, 1, 6, and 9 nM, respectively).1 It is selective for WNK1-4 over a panel of 442 kinases at 10 µM. In vivo, WNK463 (1, 3, and 10 mg/kg) decreases blood pressure, as well as increases urine output and urinary sodium and potassium excretion rates in spontaneously hypertensive rats (SHRs). It also decreases tumor growth, induces intratumoral apoptosis, and increases intratumoral levels of CD4+ and CD8+ T cells in an MC-38 mouse syngeneic colon cancer model when administered at doses of 5 and 10 mg/kg.2
WARNING This product is not for human or veterinary use.
1. Small-
2. WNK3 inhibition elicits antitumor immunity by suppressing PD-